Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Gift Director gave 315,000 shares (gift)
  2. 4 Open-market sale Chief Financial Officer sold 14,950 shares at $40.10 ($599,495)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Open-market sale Chief Financial Officer sold 7,500 shares at an average $40.17 ($301,260)
  12. 4 Open-market sale Chief Financial Officer sold 15,000 shares at an average $40.09 ($601,320)
  13. 4 Exercise or conversion Chief Financial Officer acquired 10,000 shares (option exercise)
  14. 4 Open-market sale SVP, Product Development & CTO sold 56,993 shares at an average $50.28 ($2,865,636)
  15. 4 Open-market sale Chief Financial Officer sold 14,806 shares at an average $50.07 ($741,352)
  16. 4 Open-market sale Director sold 24,800 shares at $50.11 ($1,242,728)
  17. 4 Open-market sale SVP, Product Development & CTO sold 5,637 shares at $50.00 ($281,850)
  18. 4 Open-market sale Chief Financial Officer sold 300 shares at $50.00 ($15,000)
  19. 4 Open-market sale Director sold 2,000 shares at $50.00 ($100,000)
  20. 5 Insider Annual Insider Trading Report

Page 10 of 22 · 435 filings